摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-溴-6-甲基苯甲酸甲酯 | 99548-56-8

中文名称
2-溴-6-甲基苯甲酸甲酯
中文别名
2-溴甲基-3-氯苯甲酸甲酯
英文名称
methyl 2-bromo-6-methyl-benzoate
英文别名
Methyl 2-bromo-6-methylbenzoate
2-溴-6-甲基苯甲酸甲酯化学式
CAS
99548-56-8
化学式
C9H9BrO2
mdl
——
分子量
229.073
InChiKey
DDJSNWUTQDNGIZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    141 °C(Press: 21 Torr)
  • 密度:
    1.433±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2916399090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    室温且干燥

SDS

SDS:025012f014f7c0a3423911aba39f3ac7
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Methyl 2-bromo-6-methylbenzoate
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 2-bromo-6-methylbenzoate
CAS number: 99548-56-8

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H9BrO2
Molecular weight: 229.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-溴-6-甲基苯甲酸甲酯caesium carbonate三苯基膦 、 palladium dichloride 、 lithium hydroxide 作用下, 以 四氢呋喃甲醇 为溶剂, 反应 168.0h, 生成 2-methyl-6-vinylbenzoic acid
    参考文献:
    名称:
    乙烯基芳烃羰基化选择性的超分子控制:易于获得宝贵的β-醛中间体
    摘要:
    逆流而上!据报道,一种合理设计的区域选择性加氢甲酰化催化剂[Rh / L],其中非共价配体-底物的相互作用使选择性从典型的α-醛到其他不利的产物β-醛发生了前所未有的逆转。该催化体系为精细化工行业的重要中间体开辟了新的,可持续的合成途径。
    DOI:
    10.1002/anie.201209582
  • 作为产物:
    描述:
    2-甲基-6-硝基苯甲酸 在 palladium on activated charcoal 氢溴酸氢气potassium carbonate 、 sodium nitrite 作用下, 以 乙醇丙酮 为溶剂, 20.0 ℃ 、101.33 kPa 条件下, 生成 2-溴-6-甲基苯甲酸甲酯
    参考文献:
    名称:
    全合成阿斯环素C.
    摘要:
    据报道,使用动力学控制的RCM反应形成该生物活性二芳基醚大环内酯的11元不饱和内酯环,首次合成了(+)-沥青环C(1)。
    DOI:
    10.1039/b512877c
点击查看最新优质反应信息

文献信息

  • Allylic Arylation of 1,3-Dienes via Hydroboration/Migrative Suzuki–Miyaura Cross-Coupling Reactions
    作者:Xiao-Ming Zhang、Jie Yang、Qing-Bo Zhuang、Yong-Qiang Tu、Zongyuan Chen、Hui Shao、Shao-Hua Wang、Fu-Min Zhang
    DOI:10.1021/acscatal.8b01823
    日期:2018.7.6
    The hydroboration/Pd-catalyzed migrative Suzuki–Miyaura cross-coupling of 1,3-dienes with electron-deficient aryl halides has been developed, which enables the synthesis of branched allylarenes directly from primary homoallylic alkyl boranes. A ligand-tuned linear- or branch-selective coupling for these aryl halides has also been achieved.
    1,3-二烯与缺电子的芳基卤化物的加氢硼化/ Pd催化迁移性Suzuki-Miyaura交叉偶联已经发展,这使得直接从伯均烯丙基烷基硼烷直接合成支链烯丙基芳烃成为可能。对于这些芳基卤化物,也已经实现了配体调谐的线性或分支选择性偶联。
  • Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
    申请人:Tegley Christopher
    公开号:US20050054670A1
    公开(公告)日:2005-03-10
    Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    所选化合物对于预防和治疗疾病,如介导血管生成的疾病,具有有效性。该发明涵盖了新颖的化合物、类似物、前药及其药用可接受的盐,用于预防和治疗涉及癌症等疾病和其他疾病或病况的药物组合物和方法。该发明还涉及制备此类化合物的方法,以及在此类方法中有用的中间体。
  • Heterocyclic Compound
    申请人:TAKEDA PHARMACEUTICAL COMPANY LIMITED
    公开号:US20180155333A1
    公开(公告)日:2018-06-07
    The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    本发明提供了一种具有促醒素受体拮抗活性的化合物,预计可用作药物,如预防或治疗睡眠障碍、抑郁症、焦虑症、恐慌症、精神分裂症、药物依赖、阿尔茨海默病等的药剂。 本发明涉及由以下式(I)表示的化合物: 其中每个符号如规范中定义,或其盐。
  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    申请人:Geneste Hervé
    公开号:US20130005705A1
    公开(公告)日:2013-01-03
    The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    本发明涉及新型的氨基甲酸酰胺化合物、含有它们的药物组合物及其在治疗中的应用。这些化合物具有宝贵的治疗特性,特别适用于治疗或控制神经疾病和精神疾病,用于改善与这些疾病相关的症状,并用于降低这些疾病的风险。
  • [EN] COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE PAR RAPPORT AU RECEPTEUR 5HT2C ET LEURS APPLICATIONS
    申请人:GLAXO GROUP LTD
    公开号:WO2004089897A1
    公开(公告)日:2004-10-21
    Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein R1 is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1 6alkylthio, hydroxy, amino, mono or di C1 6alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC1-6alkyl, haloC1-6alkoxy, aryl, -COOR3, -COR4 (wherein R3 and R4, are independently hydrogen or C1-6alkyl) or -COR5 (wherein R5 is amino, mono or di C1 6alkylamino or an N-linked 4 to 7 membered heterocyclic group); p is 0, 1 or 2 or 3; Q is a 6- membered aromatic group or a 6-membered heteroaromatic group; A is -(CH2-CH2)-, -(CH=CH)-, or a group -(CHR7)- wherein R7 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy or C1 6alkylthio; R2 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C1-6alkanoyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1 6alkylthio, amino, mono or di C1 6alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is oxygen, sulfur, -CH2- or NR8 wherein R8 is hydrogen or C1-6alkyl; Y is a single bond, -CH2-, -(CH2)2- or -CH=CH-; and Z is an optionally substituted N-linked heterocyclic group or a C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, or Z is -NR9R10 where R9 and R10 are independently hydrogen or C1-6alkyl. Methods of preparation and uses thereof in therapy, such as for depression or anxiety, are also disclosed.
    公开了具有式(I)的化合物及其药学上可接受的盐:其中R1是卤素、氰基、C1-6烷基、C3-7环烷基、C3-7环烷氧基、C1-6烷氧基、C1-6烷基硫基、羟基、氨基、单取代或双取代的C1-6烷基氨基、N-连接的4至7成员杂环基、硝基、卤代C1-6烷基、卤代C1-6烷氧基、芳基、-COOR3、-COR4(其中R3和R4独立地是氢或C1-6烷基)或-COR5(其中R5是氨基、单取代或双取代的C1-6烷基氨基或N-连接的4至7成员杂环基);p为0、1、2或3;Q为6-成员芳基或6-成员杂芳基;A为-(CH2-CH2)-、-(CH=CH)-或一个基团-(CHR7)-其中R7是氢、卤素、羟基、氰基、硝基、C1-6烷基、C3-7环烷基、C3-7环烷氧基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基或C1-6烷基硫基;R2是氢、卤素、羟基、氰基、硝基、C1-6烷基、C1-6烷酰基、C3-7环烷基、C3-7环烷氧基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、C1-6烷基硫基、氨基、单取代或双取代的C1-6烷基氨基或N-连接的4至7成员杂环基;X是氧、硫、-CH2-或NR8其中R8是氢或C1-6烷基;Y是单键、-CH2-、-(CH2)2-或-CH=CH-;Z是一个可选择取代的N-连接杂环基或含有至少一个氮的C-连接的4至7成员杂环基,或Z是-NR9R10其中R9和R10独立地是氢或C1-6烷基。还公开了其制备方法和在治疗中的用途,例如用于抑郁症或焦虑症。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐